Introduction
Type 2 diabetes is associated with an increased cardiovascular mortality risk ( progression of retinopathy in relation to cardiovascular morbidity and all cause mortality during a longer follow-up period. The purpose of the present study was therefore to investigate whether development of retinopathy was associated with the incidence of myocardial infarction, stroke and death during a 10-year observation period in type 2 diabetic patients.
Patients and Methods

Patients
All type 2 diabetic patients (diabetes diagnosis ≥ 30 years of age) regularly attending the Departments of Medicine and Ophthalmology, University Hospital, Lund, Sweden were included in a continuous 10-year follow-up study between 1986 and 1996. The medical examinations for all patients took place three times a year (median, range 2 to 4 times a year) and the ophthalmologic examinations at least every other year. The diagnosis of type 2 diabetes included only those who did not require insulin treatment within 2 years of diagnosis.
6
Out of 451 type 2 diabetic patients initially studied (Torffvit& Agardh 2000), 48 patients were excluded because of ketonuria at diabetes dignosis or because they were later admitted for ketoacidosis, 18 patients were lost for follow-up and data from the ophthalmological examination were not available in 22 patients. Of the remaining 363 patients (129 females) 74
were treated with oral drugs (sulfonylurea; n=37, metformin; n= 11, or both ; n=33), and 287 with insulin (191 from baseline and an additional 96 patients received insulin during the study). Twenty patients were on both oral agents and insulin.
Retinopathy
Retinal examinations took place at least every other year. The classification of retinopathy was based on fundus photographys using a 45° Topcon camera. Photography visualised three fields per eye; nasal, temporal and the macular region. In a few cases, where photographs were not available, the evaluation of retinopathy was based on a detailed description of retinopathy performed by an experienced ophthalmologist using biomicroscopy through a dilated pupil. Three retinopathy levels were used based on the worst affected eye: no retinopathy, background retinopathy, and sight-threatening retinopathy. Sight-threatening retinopathy included clinically significant macular oedema and/or severe non-proliferative 
Risk factors
Age, diabetes duration, body mass index (BMI), HbA 1c , blood pressure, urinary albumin, and serum creatinine levels were measured throughout the follow-up period. The mean logarithmic urinary-albumin, serum creatinine and the maximum of urinary albumin/ 7 creatinine clearance ratio (U-ACCR) during the 10-year follow-up was calculated.
Analytical techniques
Glycosylated hemoglobin (HbA 1c ) was analysed by ion-exchange chromatography (Bio-Rad, Richmond, CA) (1985) (1986) (1987) , by FPLC (Pharmacia, Uppsala, Sweden) (1988) (1989) (1990) (1991) (1992) (1993) (1994) ) was used for testing the difference of proportions between categorical variables. The association between heart disease, stroke or death and medical variables was investigated by the Cox regression analysis with forward stepwise selection. Retinopathy at entry and followup was included in the analysis as a variable consisting of three levels as defined above.
Progression was tested by using the difference between retinopathy degree at baseline and at follow-up. The criteria for determining variables to be added to the model were based on the maximum partial likelihood estimate. In the case of vascular morbidity or death, the "survival time" was the time from baseline to the date of event or until follow-up. In the latter case it was censored. Relative risk for an event was taken from the Cox regression analysis.
Results
Patient characteristics at baseline
At baseline 226 patients had no retinopathy, 96 background retinopathy and 41 patients sightthreatening retinopathy. Patients with sight-threatening retinopathy were older, had longer diabetes duration, higher BMI, higher levels of mean HbA 1c , systolic blood pressure, degree of albuminuria and U-ACCR compared to patients with no retinopathy, and higher BMI, degree of albuminuria and albumin creatinine clearance ratio compared to patients with background retinopathy. Patients with background retinopathy were older, had longer diabetes duration and higher systolic blood pressure compared to those with no retinopathy (Table 1) .
Baseline retinopathy and mortality
The mortality rate was higher in patients with sight-threatening retinopathy and with sightthreatening and background retinopathy during the study period compared with patients with no retinopathy (19/41 vs. 51/226; p= 0.001, and 48/137 vs. 51/226; p= 0.01), respectively. No differences were seen in the incidence of myocardial infarction or stroke during the study period between the different levels of retinopathy.
Incidence of cardiovascular complications and death in relation to development of retinopathy in patients with no retinopathy at baseline.
The development of background retinopathy was 31% (71/226) and of sight-threatening retinopathy 17% (39/226), whereas the progression from background to sight-threatening retinopathy was 51% (49/96). Patients who developed sight-threatening retinopathy more often had medical examinations than patients who did not, 5 (3-9) visits per year vs. 4 (0-9) visits per year, (median, range); (p=0.033), and had higher levels of mean HbA 1c and maximum level of albuminuria compared to both patients who did not develop retinopathy and those who developed background retinopathy, ( Table 2 ). The incidence of myocardial infarction was higher in patients who did not develop any retinopathy compared to those with 9 no retinopathy at baseline and who developed sight-threatening retinopathy (21/116 vs. 2/39; p=0.049). There was no difference regarding the incidence of stroke. Mortality rate was higher in patients who did not develop retinopathy compared to patients who developed sightthreatening retinopathy (30/116 vs. 3/39; p=0.016) and higher in patients who developed background retinopathy compared to those who developed sight-threatening retinopathy (18/71 vs. 3/39; p= 0.024). Patients who developed sight-threatening retinopathy had a longer follow-up time (9.9 ± 1.0 years) compared to patients who developed background retinopathy (8.8 ± 1.8 years; p=0.0369 and patients with no retinopathy (8.5 ± 2.6 years; p=0.001) at follow-up.
Incidence of cardiovascular complications and death in relation to progression of retinopathy
Patients who progressed from background to sight-threatening retinopathy had higher levels of mean HbA 1c levels (p=0.004) and of maximum albuminuria (p=0.041) compared to patients who did not progress. No difference in mortality rate was seen in patients with background retinopathy at baseline who continued to have background retinopathy (47/96) compared to those who developed sight-threatening retinopathy (49/96).
Relative risk -Cox regression analysis
When adjusting for systemic risk factors, i.e., age, diabetes duration, BMI, HbA 1c , blood pressure, urinary albumin, and serum creatinine levels, patients with sight-threatening retinopathy at baseline had a 2.2-fold (95% confidence interval (CI), 1.3, 3.6) increased risk (p=0.02) to die during the study compared to patients with no or background retinopathy, (Figure 1 ).
Patients with no retinopathy at baseline who still had no or background retinopathy at followup had a 3.6-fold (95% CI, 1.1,11.8) increased risk for all-cause mortality (p=0.03) compared with patients who developed sight-threatening retinopathy, still when adjusting for medical risk markers, (Figure 2 ). Since the number of patients who died in the group who developed sight-threatening retinopathy was low, Fishers Exact Test was used as complement and showed that 48/187 patients who did not develop retinopathy compared to 3/39 patients who developed sight-threatening retinopathy died, p=0.012.
Underlying causes of death
Cardiovascular complications were the cause of death in 51% of patients with no retinopathy, in 55% with background, and in 79% with sight-threatening retinopathy at baseline. For patients with no retinopathy at baseline, cardiovascular complications as an underlying cause of death in relation to retinopathy degree at follow-up were, 47% in patients with no retinopathy, 56% with background retinopathy and 67% in patients with sight-threatening retinopathy. In patients with no retinopathy at follow-up, cancer mortality and other causes (i.e. pneumonia and gastrointestinal haemorrhage) were the underlying causes of death in 50% of the patients. The different causes of mortality in relation to the development of retinopathy are shown in Table 3 .
Antihypertensive treatment
Forty-one percent of the patients who developed sight-threatening retinopathy had received treatment with ACE-inhibitors compared with 24% of the patients with no or background retinopathy at follow-up, (p=0.046). In a Kaplan -Meier analysis on overall survival time with incidence of sight -threatening retinopathy as factor and the use of ACE inhibitors as strata, treatment with ACE inhibitors was connected with a longer survival time in patients who did not develop sight -threatening retinopathy, p= 0.01.The same relation could not be confirmed in patients who developed sight-threatening retinopathy. No differences were seen in the treatment with other antihypertensive drugs, i.e., Ca-blockers, ß-blockers and diuretics.
Discussion
In this 10-year prospective study of type 2 diabetic patients, patients with background or sight-threatening retinopathy at baseline had an increased mortality compared to those without retinopathy, a finding supported by others Davis., Hiller, Magli et al 1979; Klein, Klein ,Klein& Cruickshanks 1999). However, we also found that patients with no retinopathy at baseline who developed sight-threatening retinopathy during the study period had a reduced risk for death compared to those who did not.
Retinal micro vascular abnormalities have shown to be predictive for the incidence of coronary heart disease and stroke independent of diabetes and other risk factors ( The results from the patients with no retinopathy at baseline with severe progression during the study period are a bit unexpected. Duration which is known to be a risk marker for both complications and death in diabetes was for certain longer in patients who developed background retinopathy but similar in patients who developed no or sight-threatening retinopathy. Thus the influence of duration on the results are not conclusive. Albuminuria has been reported to be an important risk marker for both cardiovascular events and death (Donnelly, Yeung & Manning 2003) , and patients who developed sight-threatening retinopathy from no retinopathy had at baseline higher levels of urinary albumin compared to patients who did not develop sight-threatening retinopathy. They had also worse metabolic control, but myocardial infarction and death were less frequent. Patients who developed sightthreatening retinopathy were medically examined more often, and one might speculate if that could have influenced the mortality from cancer and other causes. The underlying cause of mortality was cardiovascular events in 67% of patients with sight-threatening retinopathy compared to 47% in patients with no retinopathy. In patients without retinopathy the underlying causes of death were cancer and other causes in 50%. However, the number of patients who died in the group who developed sight-threatening retinopathy was few, which set limits to the interpretations of the results from the Cox regression analysis. A Fisher`s exact test could however confirm the tendency.
We acknowledge the limitation in our study, not having included lipids levels and data on current smoking. Furthermore, the follow-up time in the group who developed sightthreatening was longer and thus the patients in the other groups had less time to develop sight- . In the present study, the blood pressure was similar in patients who developed sight-threatening retinopathy and patients who did not, and almost equal to the blood pressure levels obtained in patients allocated to tight blood pressure control in the UKPDS (UK Prospective Diabetes Study Group 39, 1998), whereas the progression of retinopathy in our study was similar to those not assigned to tight blood pressure control in the UKPDS. The explanation might be the higher mean level of Abrahamian et al 1998). However, since many patients are treated with more than one antihypertensive drug, the present study can not be conclusive regarding the ACE-inhibitors effect.
In conclusion, type 2 diabetic patients with sight-threatening retinopathy at baseline had higher mortality rate whereas patients, who developed sight-threatening retinopathy had lower mortality, despite more medical risk markers, compared to patients with no-or background retinopathy at follow-up. More patients who developed sight-threatening retinopathy were treated with ACE inhibitors but this seemed not to have influenced the lower mortality rate in this group, whereas the use of ACE inhibitors in patients who did not develop sightthreatening retinopathy was connected with lower mortality rate. Table 3 . Underlying causes of death at follow-up in patients with no retinopathy at baseline.
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